Palatin Technologies specializes in developing innovative treatments for chronic inflammation by leveraging its deep understanding of the melanocortin system. The company focuses on creating potent and selective therapeutics that address unmet medical needs, particularly where current treatments fail to balance efficacy and safety. Palatin's unique approach involves engaging natural pathways to resolve harmful inflammation, allowing affected tissues to heal effectively. The company serves patients with chronic inflammatory conditions and operates in the biopharmaceutical market. Its business model revolves around research and development, with revenue generated through product sales, partnerships, and licensing agreements. Palatin's leadership team, including experienced professionals like Dr. Alan W. Dunton, drives its strategic vision and research initiatives.

Keywords: biopharmaceutical, chronic inflammation, melanocortin system, selective treatments, unmet medical needs, therapeutic development, natural pathways, tissue healing, research and development, licensing agreements.